Dataset Information

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

ABSTRACT: This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

DISEASE(S): Riss Stage I Plasma Cell Myeloma,Thyroid Neoplasms,Stage Iii Bladder Cancer Ajcc V6 And V7,Carcinoma,Ann Arbor Stage Iv Lymphoma,Chronic Myeloid Leukemia,Urinary Bladder Neoplasms,Riss Stage Ii Plasma Cell Myeloma,Stage Iv Pancreatic Cancer Ajcc V6 And V7,Breast Neoplasms,Stage Ii Lung Cancer Ajcc V7,Neoplasms,Stage Iii Prostate Cancer Ajcc V7,Chronic Lymphocytic Leukemia,Stage I Colorectal Cancer Ajcc V6 And V7,Esophageal Neoplasms,Stage Iv Uterine Corpus Cancer Ajcc V7,Carcinoma, Renal Cell,Stage Ii Prostate Cancer Ajcc V7,Stage Iii Esophageal Cancer Ajcc V7,Riss Stage Iii Plasma Cell Myeloma,Stomach Neoplasms,Malignant Hepatobiliary Neoplasm,Ann Arbor Stage Ii Lymphoma,Stage Iii Gastric Cancer Ajcc V7,Stage Ii Pancreatic Cancer Ajcc V6 And V7,Multiple Myeloma,Stage I Prostate Cancer Ajcc V7,Stage Ii Esophageal Cancer Ajcc V7,Kidney Neoplasms,Stage Iv Prostate Cancer Ajcc V7,Melanoma,Stage I Ovarian Cancer Ajcc V6 And V7,Leukemia, Myelogenous, Chronic, Bcr-abl Positive,Gastroesophageal Junction Adenocarcinoma,Stage Ii Bladder Cancer Ajcc V6 And V7,Stage Ii Breast Cancer Ajcc V6 And V7,Stage Iv Gastric Cancer Ajcc V7,Leukemia, Lymphocytic, Chronic, B-cell,Stage I Pancreatic Cancer Ajcc V6 And V7,Stage Ii Uterine Corpus Cancer Ajcc V7,Neoplasms, Plasma Cell,Stage I Gastric Cancer Ajcc V7,Stage Iii Breast Cancer Ajcc V7,Ann Arbor Stage Iii Lymphoma,Thyroid Gland Carcinoma,Stage Iii Ovarian Cancer Ajcc V6 And V7,Leukemia,Stage Ii Gastric Cancer Ajcc V7,Stage I Breast Cancer Ajcc V7,Lung Neoplasms,Stage Iv Esophageal Cancer Ajcc V7,Prostatic Neoplasms,Acute Myeloid Leukemia,Acute Lymphoblastic Leukemia,Malignant Solid Neoplasm,Colorectal Neoplasms,Ovarian Neoplasms,Stage Iv Breast Cancer Ajcc V6 And V7,Pancreatic Neoplasms,Stage Iv Bladder Cancer Ajcc V7,Stage Iv Ovarian Cancer Ajcc V6 And V7,Stage Iv Colorectal Cancer Ajcc V7,Stage Iii Uterine Corpus Cancer Ajcc V7,Stage Iii Lung Cancer Ajcc V7,Hematopoietic And Lymphoid Cell Neoplasm,Invasive Breast Carcinoma,Leukemia, Myeloid,Sarcoma,Precursor Cell Lymphoblastic Leukemia-lymphoma,Stage I Lung Cancer Ajcc V7,Lymphoma,Stage I Bladder Cancer Ajcc V6 And V7,Muscle-invasive Bladder Carcinoma,Stage Iii Pancreatic Cancer Ajcc V6 And V7,Head And Neck Carcinoma,Stage Ii Colorectal Cancer Ajcc V7,Stage I Uterine Corpus Cancer Ajcc V7,Kidney Carcinoma,Carcinoma, Ovarian Epithelial,Stage Iii Colorectal Cancer Ajcc V7,Stage I Esophageal Cancer Ajcc V7,Stage Ii Ovarian Cancer Ajcc V6 And V7,Ann Arbor Stage I Lymphoma,Stage Iv Lung Cancer Ajcc V7

PROVIDER: 2719210 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:Microarray technology has enabled the measurement of comprehensive transcriptomic information. However, each data entry may reflect trivial individual differences among samples and also contain technical noise. Therefore, the certainty of each observed difference should be confirmed at earlier steps of the analyses, and statistical tests are frequently used for this purpose. Since a microarray measures a huge number of genes and the results are processed simultaneously, concerns regarding problems of multiplicity have been raised to the tests. To deal with these problems, several methodologies have been proposed, making the tests very conservative. Indeed, arbitrary tuning of the test threshold has also been introduced to relax the test conditions. However, the appropriateness of the multiplicity problems as well as the compensation methods has not been confirmed. The appropriateness of the compensation methods was checked by means of coincidence of the premises of the methodologies with the observed characteristics found in real data of two typical platforms of microarray analysis. Normality was observed in within-group data variations, supporting applications of parametric tests. However, genes displayed their own tendencies in the magnitude of variations, and the distributions of P-values were rather complex and varied; these characteristics are inconsistent with the premises of the compensation methodologies. Additionally, the appropriateness of the proposed multiplicities is reconsidered. When we observed differences in the transcriptome, the family-wise error rate should not be considered, since analyses at higher levels would not be influenced by a few false positives among the huge numbers of true information. Likely, concerns for a false discovery rate are not suitable for the point null hypotheses on expression levels, since the rate of true null hypotheses should be rare in contradiction to the premise of the methodology. Although compensation methods have been recommended to deal with the problem of multiplicity, the compensations are actually inappropriate for many of the applications of transcriptome analyses. Compensations are not only unnecessary, but will increase the occurrence of false negative errors, and arbitrary adjustment of the threshold damages the objectivity of the tests. Rather, the results of parametric tests should be evaluated directly. This SuperSeries is composed of the SubSeries listed below.

Dataset Information

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure